Krystal Biotech (NASDAQ:KRYS) Earns Buy Rating from HC Wainwright

Key Points

• Krystal Biotech's stock received a "Buy" rating from HC Wainwright with a price target of $240.00, indicating a potential upside of 55.59% from its previous close.
• The company reported a net margin of 40.85% and earnings per share (EPS) of $1.29, which surpassed analysts' expectations of $1.08.
• Insider activity includes the sale of 1,389 shares by Suma Krishnan, amounting to approximately $208,350, reflecting a 0.09% decrease in ownership.

HC Wainwright reissued their buy rating on shares of Krystal Biotech (NASDAQ:KRYS - Free Report) in a research note published on Monday,Benzinga reports. HC Wainwright currently has a $240.00 target price on the stock.

Other equities analysts also recently issued research reports about the stock. Bank of America cut their price target on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Chardan Capital cut their price target on shares of Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a report on Friday, August 22nd. Finally, Citigroup reiterated a "neutral" rating and issued a $166.00 price target (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Krystal Biotech currently has a consensus rating of "Moderate Buy" and an average price target of $209.00.

Krystal Biotech Stock Up 1.8%

Shares of Krystal Biotech stock traded up $2.96 during midday trading on Monday, hitting $163.57. The company had a trading volume of 811,005 shares, compared to its average volume of 307,170. The stock has a market cap of $4.73 billion, a price-to-earnings ratio of 33.25 and a beta of 0.66. The company has a fifty day simple moving average of $147.98 and a 200 day simple moving average of $152.14. Krystal Biotech has a 12-month low of $122.80 and a 12-month high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported $1.29 EPS for the quarter, beating the consensus estimate of $1.08 by $0.21. The firm had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. As a group, analysts expect that Krystal Biotech will post 6.14 EPS for the current year.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 1,389 shares of the firm's stock in a transaction that occurred on Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total transaction of $208,350.00. Following the sale, the insider owned 1,508,056 shares of the company's stock, valued at $226,208,400. This trade represents a 0.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders have sold 49,800 shares of company stock worth $7,487,943. 13.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Krystal Biotech

A number of hedge funds and other institutional investors have recently made changes to their positions in KRYS. Crossmark Global Holdings Inc. lifted its position in shares of Krystal Biotech by 2.7% during the 1st quarter. Crossmark Global Holdings Inc. now owns 2,370 shares of the company's stock valued at $427,000 after buying an additional 63 shares in the last quarter. Main Management ETF Advisors LLC lifted its position in shares of Krystal Biotech by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 5,131 shares of the company's stock valued at $705,000 after buying an additional 84 shares in the last quarter. M&T Bank Corp lifted its position in shares of Krystal Biotech by 2.3% during the 2nd quarter. M&T Bank Corp now owns 3,785 shares of the company's stock valued at $520,000 after buying an additional 85 shares in the last quarter. Xponance Inc. lifted its position in shares of Krystal Biotech by 4.9% during the 1st quarter. Xponance Inc. now owns 1,873 shares of the company's stock valued at $338,000 after buying an additional 88 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC lifted its position in shares of Krystal Biotech by 6.7% during the 1st quarter. Sound View Wealth Advisors Group LLC now owns 1,515 shares of the company's stock valued at $273,000 after buying an additional 95 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).